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Abstract
Introduction—The introduction of new vaccines highlights concerns about high vaccine 
wastage, knowledge of wastage policies and quality of stock management. However, an emphasis 
on minimizing wastage rates may cause confusion when recommendations are also being made to 
reduce missed opportunities to routinely vaccinate children. This concern is most relevant for 
lyophilized vaccines without preservatives [e.g. measles-containing vaccine (MCV)], which can be 
used for a limited time once reconstituted.
Methods—We sampled 54 health facilities within 11 local government areas (LGAs) in Nigeria 
and surveyed health sector personnel regarding routine vaccine usage and wastage-related 
knowledge and practices, conducted facility exit interviews with caregivers of children about 
missed opportunities for routine vaccination, and abstracted vaccine stock records and vaccination 
session data over a 6-month period to calculate wastage rates and vaccine vial usage patterns.
Results—Nearly half of facilities had incomplete vaccine stock data for calculating wastage 
rates. Among facilities with sufficient data, mean monthly facility-level wastage rates were 
between 18 and 35% across all reviewed vaccines, with little difference between lyophilized and 
liquid vaccines. Most (98%) vaccinators believed high wastage led to recent vaccine stockouts, yet 
only 55% were familiar with the multi-dose vial policy for minimizing wastage. On average, 
vaccinators reported that a minimum of six children must be present prior to opening a 10-dose 
MCV vial. Third dose of diphtheria-tetanus-pertussis vaccine (DTP3) was administered in 84% of 
sessions and MCV in 63%; however, the number of MCV and DTP3 doses administered were 
similar indicating the number of children vaccinated with DTP3 and MCV were similar despite 
less frequent MCV vaccination opportunities. Among caregivers, 30% reported being turned away 
for vaccination at least once; 53% of these children had not yet received the missed dose.
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Discussion—Our findings show inadequate implementation of vaccine management guidelines, 
missed opportunities to vaccinate, and lyophilized vaccine wastage rates below expected rates. 
Missed opportunities for vaccination may occur due to how the health system’s contradicting 
policies may force health workers to prioritize reduced wastage rates over vaccine administration, 
particularly for multi-dose vials.
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1. Introduction
Since the 1980s, wide-scale use of vaccinations against diseases such as measles, polio, 
pertussis and hepatitis B has resulted in substantial childhood mortality reductions 
worldwide. New vaccines against pneumonia, rotavirus and other diseases are rapidly being 
introduced in low-income countries to further reduce childhood mortality. Effective vaccine 
management is continues to be crucial [1] since these new vaccines are substantially more 
expensive than existing vaccines [2]. Appropriate vaccine management includes 
recommendations to minimize vaccine wastage [1], however, concern exists about how 
wastage policies may contribute to missed opportunities to vaccinate (MOV), particularly in 
low-income countries with high vaccine-preventable disease burden [1,3–7].
A vaccine dose is considered wasted if not used to vaccinate an eligible child [6]. Global 
guidelines address ways to reduce wastage, including the multi-dose vial policy (MDVP) 
which states open vials of specific (generally liquid) vaccines can be reused up to 28 days 
[8]. However, the MDVP does not apply to lyophilized vaccines without preservative, 
including commonly used 10-dose measles-containing vaccine (MCV) and 20-dose Bacillus 
Calmette Guérin (BCG) vaccine, as they must be discarded within 6 h of reconstitution or 
end of the vaccination session (whichever comes first). The World Health Organization 
(WHO) considers the discard of remaining doses in lyophilized vaccine vials to be an 
unavoidable reason for wastage [6]. Reasons for wastage that are considered avoidable 
include: vaccine expiration, vial breakage, inappropriate vial freezing, discarding liquid 
vaccine before 28 days, prolonged heat exposure and theft of the vaccine [6]. Both unopened 
and opened vaccine wastage rates should be monitored to help determine appropriate 
response strategies [6] since unopened wastage is largely due to supply chain practices, 
whereas opened wastage is due to both supply chain and immunization practices. Globally, 
recommended maximum wastage rates range from 15% to 50% for lyophilized vaccines and 
from 5% to 25% for liquid vaccines [9,10]. How well these various policies and 
recommendations are known and implemented at the service delivery level is not well 
documented.
An MOV occurs when an individual interacts with the health system and does not receive 
the vaccines for which they are eligible [11,12]. Studies have found associations between 
wastage practices and MOV [5,13]. WHO recommends that vaccines be administered 
anytime an eligible child presents for vaccination, irrespective of the total number of 
children present in the clinic (i.e. ‘every opportunity’ or ‘vial-opening’ recommendation) 
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[6,14]. Yet, multiple MOV assessments in low-income countries using health facility exit 
interviews with child caregivers indicate that children are turned away specifically for BCG 
and MCV vaccinations [4,5]. Few studies have conducted in-depth vaccinator surveys to 
examine the decision-making processes that lead to children being turned away, particularly 
to the roles of vaccine wastage concerns and vial usage practices. Although studies have 
examined vaccine wastage rates [15–19], none have done so while also examining 
vaccinator knowledge, attitudes and practices associated with vaccine vial usage and 
management guidelines. Examining both wastage rates and related vaccinator knowledge 
and attitudes could provide a more in-depth understanding of observed vaccine usage 
patterns and assist with developing interventions to address identified issues.
In 2011, Nigeria began preparations to introduce pneumococcal conjugate vaccine, replace 
diphtheria-tetanus-pertussis (DTP) vaccine with DTP-hepatitis B-Haemophilus influenzae 
type b (pen-tavalent) vaccine and endorse a goal to eliminate measles by 2020. In this study, 
we assessed health sector staff knowledge, attitudes and practices related to vaccine vial 
usage and wastage guidelines, calculated vaccine wastage rates and usage patterns over a 6-
month period at both service delivery and storage levels, compared vaccine wastage rates 
between liquid and lyophilized vaccines to determine if rates differed based on policies such 
as the multi-dose vial policy, and evaluated child caregiver experiences with MOV. This 
information provides evidence for policy-makers in Nigeria regarding strategies to improve 
vaccination coverage, and informs future research addressing the relationship between 
wastage rates and vaccination coverage.
2. Materials & methods
2.1. Definitions
In Nigeria, routine vaccinations are generally administered by one or more trained health 
workers at health facility level. Routine vaccinations are generally administered during a 
multi-hour vaccination session, which may be held at the facility, or at an outreach site in a 
village far from the facility; one or more routine vaccines may be administered during this 
session. Health workers who provide vaccinations are supervised by local government area 
(LGA, equivalent to districts in most countries) immunization officers and vaccine 
logisticians. Vaccines are supplied from the national level to states, and then to LGAs. 
Vaccines are stored in LGA cold stores until they are needed for administration at health 
facility level. Unopened vaccine wastage is defined as loss of doses in an unopened vial; 
opened vaccine wastage is defined as loss of doses in an opened vial. A wastage rate is the 
sum of both opened and unopened wastage rates. An MOV in this study is defined as the 
event when a child eligible for vaccination attended the health facility for health services 
(vaccination, curative care) and did not receive the vaccine(s) for which they were eligible.
2.2. Sampling
We conducted two-stage random sampling of LGAs and health facilities where routine 
vaccinations are provided in each of Nigeria’s six zones and its Federal Capital Territory 
(FCT). In each zone, we used probability proportional-to-size sampling to randomly select 
two LGAs; in FCT, the team randomly selected one LGA. In each LGA, the team used 
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simple random sampling to select five health facilities – on average, 20% of the facilities in 
each LGA –to conduct vaccinator interviews. At each facility, we aimed to interview 5 
caregivers of children <24 months as they exited the facility after receiving health services 
for the child, using convenience sampling. Our total target sample was 13 LGAs, 65 health 
facilities and 325 caregivers.
2.3. Data collection
2.3.1. Data collection team and activities—Data collection occurred in August 2011. 
The data collection team was composed of national and state vaccine logistics officers 
employed at Nigeria National Primary Health Care Development Agency (NPHCDA) and 
UNICEF. We assigned logistics officers as data collectors in areas where they were not 
employed to minimize interviewer bias. In selected LGAs, data collectors interviewed the 
LGA immunization officer (who supervises health facility vaccinators) and vaccine 
logistician (who maintains the LGA-level vaccine supply chain) and reviewed vaccine stock 
records. At health facilities, data collectors interviewed the health worker who provided the 
majority of the vaccinations (whom we refer to as the vaccinator) and reviewed vaccine 
stock and vaccination session records. The data collectors also conducted facility exit 
interviews with caregivers of children aged <24 months who had received any health 
services.
2.3.2. Information collected—To calculate monthly LGA and health facility wastage 
rates and assess vaccine usage patterns, data collectors abstracted vaccine stock management 
data from January through June 2011 from vaccine management ledgers designed to track 
routine use of vaccine. Abstracted data per month were: starting monthly balance of vaccine 
doses, number of vaccine doses received from a higher administrative level, vials opened 
(collected at facility level only), number of children vaccinated (collected at facility level 
only), ending monthly balance of vaccine and reason for discard of unopened doses 
(expiration, breakage, VVM status, freezing, other).
To calculate vaccination session wastage rates and assess usage patterns, data collectors 
abstracted vaccination session data for the immediately preceding three months (June–
August 2011) from vaccination session tally sheets used to tally vaccine use per daily 
vaccination session. Abstracted data per session were: number of vials received, vials 
opened, vials returned unopened and children vaccinated per session. We abstracted data for 
the following vaccines: DTP, MCV, BCG, oral polio vaccine (OPV), tetanus toxoid (TT) and 
hepatitis B (HepB).
We used Nigeria’s national vaccination guidelines [20] (Table 1) and WHO policies and 
guidelines [6,21] to develop KAP questionnaires. Health workers at the LGA and facility 
level were asked about their knowledge of target wastage rates, how they managed vaccine 
stock, and how they monitored and reported on vaccine stock and storage indicators. 
Additionally, they were asked about awareness and implementation of the MDVP and ‘vial-
opening’ guidelines, perceived influence of wastage on vaccine supply, strategies used to 
manage wastage, and factors leading to high wastage rates. Lastly, caregivers were 
interviewed about whether they had been turned away for vaccination recently, which 
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vaccines they were seeking when turned away, and whether they had returned later for the 
missed vaccination.
2.4. Data analysis
All data were collected on paper and then entered into Micro-soft Excel. All analyses used 
survey procedures in SAS 9.2 and were weighted based on the sampling design.
2.4.1. Datasets for calculating vaccine wastage and assessing usage patterns
—Using abstracted data, we created datasets for (1) LGA-level vaccine stock data, (2) health 
facility vaccine stock data, and (3) vaccination session vaccine vial usage. All vial data were 
converted to into doses. Monthly or session records for a vaccine were excluded from 
analysis if they were not interpretable for any of the following reasons:
• Data for a vaccine were missing for either the number of doses administered or 
the number of vials opened;
• The number of doses administered to children exceeded the number of vials 
opened for use
• For session data only: the number of doses returned to cold chain exceeded the 
number of doses expected to be returned based on number of doses supplied and 
number of doses used
We used WHO-recommended formulas for calculating wastage (WHO, 2005). Before 
analyses, we assessed the monthly availability of data for each indicator in the formula.
2.4.2. Calculation of facility (service-delivery) level vaccine wastage—Due to 
data availability concerns, we calculated facility-level wastage rates using data from two 
sources: vaccine stock management ledger datasets and vaccination session monitoring form 
datasets. The following formula was used for calculating monthly vaccine-specific wastage 
rates using data from the vaccine stock management ledger dataset:
We calculated unopened and opened vaccine-specific wastage rates using the following 
formulas:
To obtain a monthly mean of wastage rates across facilities, we calculated a mean across all 
six months per facility and then calculated a mean across all facility means. The following 
formula was used for calculating vaccine-specific wastage rates per session using data from 
the vaccination session monitoring form dataset:
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To obtain a monthly mean across all sessions, we calculated a mean across all sessions per 
facility and then calculated a mean across all session means. We also summed the total 
number of doses of each vaccine administered across all sessions to determine if any 
differences were present in this indicator across vaccines.
2.4.3. Calculation of LGA (storage-level) vaccine wastage—Since vaccines are 
only stored and not administered at the LGA level, we used the following formula to 
calculate unopened LGA-level vaccine-specific wastage rates:
We then calculated a monthly vaccine-specific mean per LGA and then calculated a mean 
across these LGAs.
We also calculated presence of a monthly facility-level vaccine stockout (i.e. when no 
vaccine is available) by analyzing whether the monthly vaccine stock balance per the 
vaccine stock management ledger was equal to zero for the entire month (i.e. monthly 
opening balance, number of vials received and monthly closing balance were all equal to 0).
2.4.4. Analysis of vaccine usage patterns during vaccination sessions—We 
calculated the proportion of sessions where each vaccine was given and the mean number of 
doses given per session for each vaccine (in sessions where ≥1 doses were administered). We 
also calculated the total number of doses given per vaccine across all sessions.
2.4.5. Statistical analysis of interview data—For categorical indicators, we calculated 
proportions and 95% confidence intervals (95% CIs) based on our sampling method. For 
numerical indicators, we calculated means and 95% CIs. We used t-tests for comparing 
means and Rao-Scott chi-square tests for comparing proportions and an alpha level of 0.05 
for any hypothesis testing of differences between two indicators.
3. Results
Data were collected from 11 (85% of target) LGAs, 54 (83% of target) facilities and 263 
(81% of target) caregivers across 6 zones and FCT; remaining target areas were excluded 
due to security concerns that arose during data collection. We abstracted and analyzed 576 
vaccination session records, 324 months of facility-level stock management records and 66 
LGA-level stock management records.
3.1. Vaccine stock and vaccination session data availability and quality
Among LGA stock records, 36% provided sufficient data to calculate LGA-level wastage 
rates. Among health facility stock records, a mean of 51–55% of facilities (varying by 
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vaccine) had sufficient data to calculate facility-level wastage rates. Data were most 
commonly missing for number of vials received (23–34% of facilities without data, varying 
by month), number of vials opened (37–39%) and number of vials returned unopened (41–
43%). No facilities distinguished opened from unopened wastage, so unopened vaccine 
wastage rates could not be calculated. Using facility-level vaccination session records, 24–
41% (varying by vaccine) of sessions provided sufficient data to calculate facility-level 
wastage rates.
3.2. LGA and facility-level vaccine supply and wastage rates
LGA-level unopened vial wastage rates were 0% for all vaccines and months in all LGAs 
except for 20% BCG wastage in one LGA for one month. Using vaccine stock records, the 
mean monthly facility-level wastage rate during the 6-month period was highest for TT 
(28%) and lowest for DTP (18%) (Fig. 1, Table 2). Using vaccination session records, the 
mean monthly wastage rate was highest for OPV at 35% and lowest for DTP vaccine at 
21%. On a month-by-month basis, mean facility-level wastage rates were all under 34%, 
ranging 16–34% for BCG, MCV, OPV and TT, and 9–25% for HepB and DTP [data not 
shown].
The mean monthly proportions of facilities with stockout of BCG or OPV were 42% and 
32%, respectively. For all other vaccines, the mean monthly proportions were 5–15%.
3.3. Vaccination session vaccine usage patterns
On average, facilities held vaccination sessions 3.6 times per month, with 44% conducting 
vaccination sessions more than once per week. HepB1, HepB3, DTP1 and DTP3 were all 
administered in >77% of the 576 reviewed sessions (Table 2) MCV and BCG vaccines were 
administered in a significantly lower proportion of sessions (63%, and 26%, respectively; p-
value < 0.02 for all pairwise comparisons) compared to DTP1 (86% of sessions) and DTP3 
(84% of sessions). Although MCV was administered in fewer sessions, the total number of 
MCV doses administered across all sessions (4740) was slightly higher than the number of 
DTP3 doses administered (4286). In sessions with MCV vaccination, a mean of 10.0 doses 
(range = 1–38), were administered per session; in comparison, during sessions with DTP 
vaccination, a mean of 7.5 DTP1 doses (range = 1–70) and 6.7 DTP3 doses (range = 1–51) 
were administered per session. A slight majority (51%) of sessions with MCV vaccination 
involved administration of 7–10 doses from the presumed final MCV vial used in a session 
(i.e. sessions with 7–10, 17–20, 27–30, or 37–38 total MCV doses administered) and the 
highest proportion of sessions (20%) involved 8 administered doses from the final vial, i.e., 
8, 18 or 28 doses given in a session (Fig. 2). In 61% of sessions with BCG administration, 
11–20 doses from the final BCG vial were administered (data not shown).
3.4. Vaccine stock management and monitoring knowledge and practices
Nearly all (97%) vaccinators requested vaccine when stocks were low; the remaining 3% 
reported that the LGA sent vaccine to the facilities based on LGA-level estimates of vaccine 
need (Table 3). When determining the number of vials to request, 53% of vaccinators 
reported using the number of doses administered in previous vaccination sessions, 33% used 
their target population and the remaining 12% were uncertain.
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Routine stock management monitoring was infrequent; 18% of vaccinators monitored cold 
chain temperatures twice daily, and 9% routinely calculated wastage rates (Table 3). No 
vaccinators monitored unopened-vial wastage although 39% indicated lost or damaged 
unopened vials in the previous six months. Few vaccinators (12%) knew the national 
wastage rate targets or the variables needed to calculate wastage rates (16%). Although most 
(91%) LGA staff knew the national wastage rate targets and most (83%) routinely monitored 
wastage rates, but only 38% could accurately recall the proper information needed to 
calculate wastage.
3.5. Knowledge and implementation of vaccine usage policies
When asked about the re-use of an opened liquid vaccine vial with remaining doses, 
vaccinators at 55% of facilities reported they were familiar with the MDVP-defined 
conditions for re-use (Table 3). However, <50% of vaccinators could, without prompting, 
recall specific MDVP conditions for re-use and only 11% knew an opened liquid vaccine 
vial could be re-used up to 28 days. Contrary to MDVP recommendations, 47% reported 
discarding opened, reusable polio vaccine at the end of a vaccination session rather then 
returning it to the cold chain. Among vaccinators who were familiar with the MDVP, 76% 
reported reusing an opened polio vaccine vial, versus only 10% among those vaccinators 
who were unfamiliar with the MDVP (odds ratio = 27.1, p-value < 0.01) [not shown].
When vaccinators were asked how they decide to open any vial, 54% stated they open vials 
on pre-scheduled vaccination session days. When specifically asked how they decide when 
to open an MCV vial, 98% of vaccinators stated they open only on a special MCV 
vaccination day or wait for a certain minimum number of children, while only 2% open for 
any eligible child present (Table 3). Sixty percent stated that they “batch” children, i.e. 
waiting for a desired number to arrive during a session, before deciding to open an MCV 
vial. On average, vaccinators reported that 6 (95% CI: 5–7) children needed to be present 
before they would open a MCV vial.
In comparison to vaccinators, 6% of LGA staff reported that an MCV vial should be opened 
anytime a child presents for vaccination and 77% stated an MCV vial should be opened 
either if a certain number of children are present or if it is a scheduled MCV vaccination day. 
All LGA staff reported familiarity with MDVP but only 35% knew opened vials of liquid 
vaccines could be used up to 28 days.
3.6. Knowledge, attitudes and practices regarding wastage
Nearly all vaccinators (98%) perceived vaccine wastage to be a cause of recent vaccine 
stockouts (Table 3) and 79% indicated they made efforts to reduce wastage. Most (78%) 
vaccinators indicated they were told during supervision visits from LGA level of the need to 
reduce vaccine wastage. Strategies used by vaccinators to reduce wastage included 
improving stock management (reported by 48% of vaccinators), better community 
mobilization (38%), batching children (25%) and implementing the MDVP (19%). When 
asked to list the reasons why wastage can happen, vaccinators’ knowledge was highly 
variable; many cited vial breakage (58%), discarding doses 6 h after reconstitution (43%) 
and vial exposure to high temperature (37%) [Data not shown]. When asked to list the 
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reasons why wastage happened at their own health facility, vaccinators most frequently cited 
vial spillage (57%) and inability to retrieve all doses from the vial (34%). At the LGA level, 
staff believed the leading reasons for facility-level wastage were discarding doses six hours 
after reconstitution (47%) and inability to retrieve all doses from the vial (28%). To manage 
wastage, LGA staff most frequently recommended improved stock management (53% of 
LGA staff), better-organized outreach sessions (46%) and batching children (41%).
3.7. Caregiver-reported missed opportunities
During exit interviews with caregivers of a child <24 months of age, 90% reported the child 
had received at least one routine vaccination [data not shown]. Of these, 52% reported that 
their infants received the most recent vaccination during a first attempt at attending a 
vaccination session, 40% received the vaccination on a second attempt (and were turned 
away in the first attempt), and 8% were unsure. Among the 40% turned away, the primary 
reported reason for being turned away was lack of vaccine or lack of a vaccination session 
(41%). Among all caregivers, 30% reported bringing their child for vaccination and being 
turned away at least once. Of these, 33% reported being turned away for BCG, 26% for 
MCV, 19% for HepB, 12% for DTP and 10% for other vaccines Approximately half (47%) 
of the 30% turned away reported the child had eventually received the missed vaccination 
while the other half (16% of all mothers) had not yet returned for the missed vaccination.
4. Discussion
To our knowledge, this study is the first to simultaneously assess vaccine wastage rates, 
vaccine usage patterns, and vaccinators’ knowledge, attitudes and practices regarding 
implementation of a country’s policies for managing and using vaccine. We documented that 
vaccinators’ reported practices regarding when they open a vial for certain vaccines differs 
from global, national and supervisors’ guidelines while their knowledge of recommended 
vaccine usage and wastage practices was suboptimal. Estimated monthly wastage rates were 
near 25% for all vaccines and differed little between liquid and lyophilized vaccine 
presentations, indicating that vaccinators could be overly focused on minimizing wastage for 
lyophilized vaccines but not fully implementing recommended policies like the MDVP to 
minimize wastage further for liquid vaccines. Quality of vaccine stock record data was 
inadequate, and unopened versus opened vial wastage was not monitored despite reports that 
both types of wastage occurred. MCV and BCG were administered in significantly fewer 
sessions compared to DTP3; suggesting children may experience MOVs if they came during 
sessions when MCV and BCG were not given. However, MCV and DTP3 coverage rates 
were similar, suggesting that children who are turned away for MCV may eventually return 
to receive it at the same rate as DTP3 receipt. Lastly, caregivers reported being turned away 
for vaccination, most frequently for BCG and MCV, and a substantial proportion had not yet 
received the missed vaccine. These missed opportunities lead to under-vaccination (or late 
vaccination) against measles and tuberculosis at a vulnerable age for the child and contribute 
to an increase in the unprotected cohort size.
Despite global and national recommendations to ensure a vaccine vial is opened at every 
opportunity, our study indicates vaccinators may prioritize minimizing wastage over opening 
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a vial for every eligible child, risking the achievement of timely, complete and cost-effective 
immunization. In our study, the administration of MCV and BCG vaccine during special 
MCV/BCG vaccination days and/or when a minimum number of children are present was 
evident not only from vaccinator reporting but also from vaccination session data. This may 
partly explain why liquid and lyophilized vaccine wastage rates are similar despite country 
and global guidelines stating that acceptable wastage rates are higher for MCV (up to 
wastage of 50%) and BCG compared to other vaccines [10,20]. In other countries where 
implementation of policies around when to open a vial may differ from that in Nigeria, 
substantial differences between lyophilized and liquid vaccine wastage rates have been 
observed [16]. In Nigeria, the number of MCV and DTP3 doses provided in the analyzed 
sessions were similar, which may indicate that even if infants are turned away for MCV, 
eventually they receive MCV at similar levels as DTP3. However, delayed vaccination can 
lead to increased economic burden for the caregiver who travels multiple times for the same 
vaccination and prolonged period of disease risk for children. In recent measles outbreaks in 
Ethiopia and other African countries, substantial disease burden occurred among children 9–
12 months of age, indicating the need to ensure a timely dose at 9 months of age in high 
burden settings [22,23].
Vaccinators may employ multiple strategies to minimize vaccine wastage without causing 
missed opportunities. Proper vaccination session planning, delivery of key reminder 
messages to mothers during the vaccination session and use of a community-level mobilizers 
to inform mothers of vaccination session dates can also reduce the number of mothers who 
accidently come on non-vaccination days [24]. Ensuring vials are opened at every 
vaccination opportunity, despite the likelihood that wastage could occur, guarantees a child 
will be vaccinated and at reduced risk of infection. Multiple strategies exist to ensure 
policies to reduce missed opportunities are prioritized over wastage concerns, including 
health program manager and health worker trainings and dissemination of job aids to 
workers. Vaccine forecasting may also need to incorporate the expectation that wastage rates 
for lyophilized vaccines may rise to incorporate vial-opening practices, which reduce missed 
opportunities. Future work should examine the relationship between MCV vaccine wastage 
rates and MCV vaccination coverage and couple this assessment with cost-effectiveness 
analyses of interventions designed to address wastage-coverage relationship. For instance, 
changing the MCV vaccine vial size from 10 doses to 5 doses may nudge vaccinators into 
opening a vial, although the impact of such a change on timely coverage, wastage rates and 
associated costs is unknown [25,26]. Additionally, our results of relatively high wastage 
rates for MDVP-eligible liquid vaccines (i.e. OPV and DTP) which could be re-used for up 
to 28 days, coupled with low levels of MDVP vaccinator knowledge indicate the need to 
address the MDVP in health worker trainings. Such activity could appropriately reduce 
liquid vaccine wastage rates and save costs, while not leading to MOVs.
Our study is subject to certain limitations. Our facility sample size is small, affecting the 
precision of our estimates. A substantial number of facilities had incomplete vaccine 
management records which may have introduced bias in our estimates; we are uncertain the 
direction of this bias. We only reviewed vaccine usage patterns for 6 months, so our data 
may be affected by seasonal differences. Our caregiver survey was a convenience sample of 
those who came to the health facility to use health services and was not representative of the 
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general population. Additionally, do to increasing security restrictions during the study 
period, we had to eliminate certain areas that were initially selected for the survey, which 
could introduce selection bias issues. Lastly, caregiver reasons for being turned away were 
based on self-report and not individually verified with vaccinators.
Low-income countries like Nigeria face pressure to minimize vaccine wastage, and this may 
result in vaccinators diverging from acceptable methods and practices intended to ensure 
high and timely vaccination coverage. When faced with a single child who presents for 
MCV vaccination, vaccinators must choose whether to turn the child away or to immediately 
vaccinate the child, potentially resulting in high wastage and vaccine stockout. National 
level immunization teams should examine the implementation of vaccine management 
policies at the service delivery level and then appropriately adjust vaccine procurement and 
supply, health worker training materials and other efforts to ensure that missed opportunities 
are minimized while wastage rates are appropriately managed. National staff should also 
explore utilizing facility-based supervision visits to monitor implementation of 
recommended vaccine management and usage policies to reinforce the theme of reducing 
missed opportunities while appropriately managing vaccine wastage.
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Fig. 1. 
Mean monthly vaccine wastage, by vaccine, for health facilities and vaccination sessions; 
selected Nigerian health facilities, 2011. Facility stock-based records wastage calculated 
using data from health facility monthly stock management ledgers. Session-based records 
wastage calculated using data from vaccination session ledgers. Numbers in parentheses 
represent number of health facilities with data available to calculate given wastage rate. 
Error bars represent the 95% confidence interval for given estimate. Broken lines indicate 
target maximum wastage for lyophilized vaccines (MCV and BCG) and for liquid vaccines 
(all others listed) based on 2011 Nigeria national vaccination policy. BCG = Bacillus 
Calmette-Guérin vaccine; OPV = oral polio vaccine; DTP = diphtheria-tetanus-pertussis 
vaccine; HepB = hepatitis B vaccine; TT = tetanus toxoid.
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Fig. 2. 
Number of measles-containing vaccine (MCV) doses administered at vaccination sessions at 
54 health facilities, Nigeria 2011 (N = 390 vaccination sessions where MCV was 
administered).
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Table 1
Vaccinations recommended and vaccine vial presentations used in Nigeria in 2011.
Vaccine
Number of 
doses per vial Type
Target 
maximum 
wastage rate Recommended schedule
Bacillus Camille-Guérin vaccine 20 Lyophilizeda 50% 1 dose: Birth
Oral polio vaccine 20 Liquid 15% 4 doses: Birth and ages 6 weeks, 10 weeks, 14 
weeks
Diphtheria-tetanus-pertussis vaccine 10 Liquid 15% 3 doses: ages 6 weeks, 10 weeks, 14 weeks
Hepatitis B 10 Liquid 15% 3 doses: ages 6 weeks, 10 weeks, 14 weeks
Measles-containing vaccine 10 Lyophilizeda 50% 1 dose: age 9 months
Yellow fever 10 Lyophilizeda 50% 1 dose: age 9 months
Tetanus toxoid 10 Liquid 15% 4 doses: Child-bearing age women
aOnce opened, vaccine must be used within 6 h of reconstitution or by the end of the vaccination session, whichever comes first; otherwise, all 
remaining doses are discarded.
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Table 3
Knowledge, attitudes and practices regarding vaccine vial usage and vaccine wastage among vaccinators at 54 
selected health facilities and their supervisors at 11 selected local government areas (LGAs) of Nigeria, 2011.
Indicator
Vaccinator (N = 54); 
% responding “yes”, 
(95% CI)
LGA supervisor (N = 
11); % responding 
“yes”, (95% CI)
General vaccine wastage-related knowledge and attitudes:
I am familiar with the multi-dose vial policy (MDVP) 55 (0, 100) 100 (100,100)
 MDVP knowledge: I can reuse an open vial of an eligible vaccine if stored in 
appropriate cold chain conditions
33 (5, 61) 100 (100,100)
 MDVP knowledge: I can reuse an open vial of an eligible vaccine if vaccine vial 
monitor is in stage 1 or 2
43 (9, 78) 64 (3, 100)
 MDVP knowledge: I can reuse an open vial of an eligible vaccine for up to 28 days 11 (0, 29) 35 (0, 96)
I received vaccine wastage targets from supervisor 12 (0, 25) 91 (68,100)
Vaccine supply has been affected by vaccine wastage 82 (42, 100) 38 (6,70)
There was wastage due to vaccine storage space constraints 0 (0, 1) NA
High wastage rates were a reason for recent vaccine stockouts 98 (93, 100) NA
I have attended a vaccine management training 2 (0, 5) NA
General vaccination-related practices:
In general, a vial is opened as soon as an eligible child comes to the facility 46 (0, 100) 76 (42, 100)
In general, a vial is opened only on certain days or when a certain number of children 
are present at the facility
54 (0, 100) 24 (0, 59)
Measles-containing vaccination-related knowledge:
Re-constituted measles-containing vaccine (MCV) can be kept for up to 6 h 85 (65, 100) NA
Measles-containing vaccination-related practices:
An MCV vial is opened as soon as an eligible child comes to the facility 2 (0, 5) 6 (0, 20)
An MCV vial is opened only on certain days or when a certain number of children are 
present at the facility
98 (95, 100) 77 (48, 100)
I wait for children to gather to a minimum number before opening a MCV vial 60 (25, 95) NA
General vaccine wastage-related practices:
I forecast vaccine needs based on target population 33 (3, 64) NA
I forecast vaccine needs based on previous number of vaccines used 53 (11, 94) NA
I request vaccine from LGA when needed (pull approach) 97 (92, 100) NA
I make an effort to reduce wastage 79 (63, 96) 79 (35, 100)
Vaccines were wasted due to cold chain failure at least once in the last six months 35 (0, 78) NA
Vaccine vials were lost/damaged at least once in the last six months 39 (24, 54) NA
I calculate wastage rates monthly for each vaccine 9 (0, 20) 83 (51, 100)
I calculate open vial wastage rates monthly for each vaccine 0 (0, 0) NA
I know the vaccine wastage rate targets 12 (0, 25) 91 (68, 100)
I know the variables needed to calculate wastage 16 (0, 31) 38 (0, 100)
I monitor cold chain temperatures twice daily 18 (6, 30) NA
I discard opened, usable polio vaccine vial at the end of session 47 (5, 89) NA
The national policy for when to open a vial is different than the practice in my LGA NA 36 (5, 67)
The practice in this LGA on use of the multi-dose vial policy is different than the official 
policy
NA 7 (0, 22)
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Indicator
Vaccinator (N = 54); 
% responding “yes”, 
(95% CI)
LGA supervisor (N = 
11); % responding 
“yes”, (95% CI)
Main reasons why wastage occurs at your facility(s)
Spillage of vaccine 57 (30, 86) 12 (0, 31)
Inability to get all doses from vial 34 (6, 64) 28 (0, 64)
Discard 6 h after reconstitution 31 (11, 5) 47 (0, 100)
Exposure to high temperature 16 (0, 34) 35 (6, 64)
Breakage of vial 11 (0, 25) 0 (0, 0)
Exposure to freezing 5 (0, 18) 6 (0, 17)
Discarding an open vial with usable vaccine 1 (0, 4) 9 (0, 25)
Definitions: NA = statement not applicable or asked to this level; LGA = local government area; CI = Confidence interval; MCV = measles-
containing vaccine; MDVP = multi-dose vial policy. For the MDVP, an eligible vaccine was described as those vaccines which could be stored past 
the 6-h mark after opening of the vial and vaccine was still in the vial.
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